Authors' recommendations: The main reason for the original CDEC recommendation of "Do Not List" was a lack of sufficient evidence to establish the comparative efficacy of lurasidone against other AAPs. In this updated review, no additional RCTs meeting the inclusion criteria have been identified since the original CDR review of lurasidone. Without direct comparative trials, a recently published NMA provided important insights into the comparative efficacy and safety of AAPs, including lurasidone, in the acute-treatment setting. The results indicated that lurasidone was associated with lower efficacy in terms of PANSS total score than olanzapine and risperidone. Although there were no significant differences in efficacy between lurasidone and aripiprazole, quetiapine, or ziprasidone, lurasidone was ranked as least efficacious among these drugs. Weight changes with lurasidone were similar in magnitude to aripiprazole and ziprasidone, and less than with older AAPs. There was no information regarding relative effects on other metabolic parameters. Compared with the original CDR review, there was no additional information regarding the relative long-term efficacy and safety of lurasidone compared with other AAPs. An important context for interpreting the available evidence for lurasidone is patient group input, indicating the need for additional therapeutic options for schizophrenia.

Project Status: Completed

Year Published: 2014

URL for published report: http://www.cadth.ca/media/cdr/clinical/SR0331_Latuda_CL_Report_e.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)